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Simvastatin is a cholesterol lowering statin whose adverse effects include an 
increase in appetite and, consequently, obesity. This is counterproductive to the 
otherwise beneficial outcomes of simvastatin on metabolic and cardiovascular 
health. The mechanisms underlying simvastatin-induced hyperphagia are 
unknown. This thesis investigated whether central mechanisms contribute to 
simvastatin-induced increase in appetite by using a laboratory rat model. First, the 
effect of intracerebroventricularly (ICV) administered simvastatin on the energy-
driven intake of ‘bland’ chow, and on reward-motivated consumption of palatable 
solutions was determined. The data indicated that ICV simvastatin moderately 
increases ingestion of energy-dense chow, but it does not affect consumption of 
calorie-dilute and non-caloric palatable sucrose or saccharin solutions. It suggests 
that simvastatin acting directly at the brain level elevates intake of energy, while 
being ineffective in stimulating eating for reward. Surprisingly, rats injected ICV 
with simvastatin also consume significantly more water after water deprivation, 
which points to a relationship between centrally acting simvastatin and thirst-
related processing. In the second part of this project, the effect of an orexigenic 
dose of ICV simvastatin on neuronal activation in consumption-related 
hypothalamic sites was investigated. Simvastatin elevated c-Fos 
immunoreactivity, which serves as a marker of neuronal activation, in the arcuate 
and paraventricular nuclei. These two sites have a profound influence on the 
regulation of energy intake and energy balance, as well as an effect on water 
balance. It can be concluded that simvastatin increases intake of energy and of 
water, and that it likely exerts its action through the hypothalamic paraventricular 
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6 Identification of central mechanisms underlying 
statin-induced changes in consummatory behaviour in 
rats 
6.1 Introduction  
Statins are a common class of drug prescribed to maintain proper cholesterol 
levels due to their efficiency at reducing low density lipoprotein cholesterol 
(LDL-C) (Weng, Yang, Lin, & Tai, 2010). They have been shown to decrease 
LDL-C levels by between 40 to 60%, making them a great tool to fight 
cardiovascular disease (CVD) and related adverse effects (Law, Wald, & 
Rudnicka, 2003)  
Statins are used by a significant proportion of the population, with 20% of 
American adults being prescribed statins at some point in their lives due to high 
cholesterol levels, and a further 200 million people using them worldwide for the 
same reasons (Blaha & Martin, 2013; Mercado et al., 2015).  
These drugs are prescribed for two reasons: genetic predisposition to CVD, and 
leading a lifestyle that is conducive of CVD. The genetic analyses and 
characterisation of CVD risk alleles is becoming more comprehensive with the 
use of genetic markers. Genetic markers include previously discovered gene 
groups such as many of the apolipoprotein (apolipoprotein A1, A4, B, C3 and E) 
and interleukin genes (interleukin 4 and 6) (Reis et al., 1997; Stavljenic-Rukavina, 
2002). More recent discoveries of genetic markers for CVD include endocan, 
urate transporter GLUT9, osteoprotegerin and LDL receptor gene (Balta et al., 
2015; Goldstein & Brown, 2009; Mallamaci et al., 2015; Singh, Kumar, Tewari, 
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& Agarwal, 2017). The use of genetic markers has made it easier to identify 
individuals susceptible to CVD, and has led to the identification of 
polymorphisms in genes which contribute to CVD. Due to the advancement of 
genetic marker use, over 1100 mutations in the LDL receptor gene have been 
found which contribute to the dysfunction of the LDL receptor (Goldstein & 
Brown, 2009). The mutations within the LDL receptor gene are associated with 
the most common CVD promoting disease, familial hypercholesterolemia (Austin, 
Hutter, Zimmern, & Humphries, 2004). Familial hypercholesterolemia is a 
hereditary condition where the ability to metabolise LDL-C is impaired (Goldstein 
& Brown, 2009). In addition, genetic markers have also identified a range of 
polymorphisms which are associated with other diseases that contribute to CVD 
such as coronary heart disease and cerebrovascular disease (Bhatnagar, 
Wickramasinghe, Williams, Rayner, & Townsend, 2015).  
Statins are required for people whose impaired physiology are unable to properly 
metabolise LDL-C, and lifestyle choices can exacerbate the outcome from genetic 
predisposition to CVD. Dietary choices such as high sodium consumption, high 
processed meat consumption and low calcium in the diet may intensify genetic 
predisposition to CVD (Graudal, Hubeck-Graudal, & Jürgens, 2012; Micha, 
Wallace, & Mozaffarian, 2010; Slinin, Foley, & Collins, 2005).  
Although these drugs are vital for people who fall into this category, they have 
also been associated with adverse off-target effects. These effects described by 
patients range from having a mild impact on health and wellbeing, such as nausea 
and fatigue, to effects considered critical for positive health outcomes such muscle 




Increased risk to develop obesity has gained a great deal of attention. While the 
risk of developing CVD due to genetic components and lifestyle choice is 
decreased by statin use, energy dysregulation causing weight gain is also observed 
and may not only counteract this beneficial outcome, but exacerbate the effects of 
CVD. The increase in body weight (BW) may reflect an influence simvastatin, a 
type of statin, has on appetite which needs to be further investigated.  
Therefore, it is imperative to understand how these drugs work and the 
mechanisms behind their off-target effects. Consequently, we can then gain 
knowledge of how to mitigate an increase in BW caused by simvastatin, and 
instead promote its intended use.  
To uncover the mechanisms behind simvastatin induced weight gain, this thesis 
explores the underlying molecular pathways behind CVD development and how 
statins fit into this system. Both the peripheral and central mechanisms behind 
food intake will be discussed, as well as the neural pathways behind eating for 
energy and eating for pleasure. Ultimately, this thesis attempts to explain how 
simvastatin is influencing food intake with possible suggestions around reversing 




6.2 Atherosclerosis, cholesterol regulation and statin function  
6.2.1 The progression of atherosclerosis 
CVD is becoming increasingly common; thus, it is crucial that statins are utilised 
in order to reduce complications that arise from atherosclerosis (Ministry of 
Health, 2016). Atherosclerosis is a gradual process where plaques are formed 
beneath the endothelium of arteries (P. Libby, Ridker, & Hansson, 2011). These 
plaques narrow the arteries, putting stress on the cardiovascular system and 
increasing the risk of a major coronary event or stroke (Jurkovitz, Abramson, 
Vaccarino, Weintraub, & McClellan, 2003). The most common hypothesis for the 
progression of atherosclerosis is the oxidative modification hypothesis. This was 
first proposed by Michael S Brown and Goldstein (1983) who showed chemical 
modifications to LDL could increase their affinity for macrophage uptake. 
Research that lead on from this initial finding suggests oxidation of LDL-C has a 
role in the initiation of atherosclerosis and is partially responsible for the 
formation of fatty plaques (Steinberg, 2009).  
The mechanisms behind the progression of atherosclerosis is continuously being 
updated with new research. However, the current explanation states that the 
progression of atherosclerosis begins with LDL-C passing through the 
endothelium and accumulating in the tunica intima via vesicles, leaky junctions or 
both (Figure 1) (Dabagh, Jalali, & Tarbell, 2009). Vesicular transportation of 
LDL-C is hypothesised to occur via endocytosis, fluid endocytosis (non-receptor 
dependent) and transcytosis by endothelial cells (Snelting-Havinga et al., 1989; 
Vasile, Simionescu, & Simionescu, 1983). In addition to this, the cell turnover – 
leaky junction hypothesis suggests that during mitosis and apoptosis of 
endothelial cells, LDL-C can pass through the weakened endothelium due to its 
5 
 
increased permeability (Lin, Jan, & Chien, 1990; Weinbaum, Tzeghai, Ganatos, 
Pfeffer, & Chien, 1985). The LDL-C then becomes oxidised through one of 
several different methods such as reacting to lipoxygenase, copper and 
ceruloplasmin, iron or peroxynitrite (Parthasarathy, Raghavamenon, Garelnabi, & 
Santanam, 2010). Oxidised LDL-C (OxLDL-C) can then initiate the release of 
cytokines such as interleukin-1 (IL-1) (Bonow, Mann, Zipes, & Libby, 2011). IL-
1 increases expression of chemoattractants such as monocyte chemoattractant 
protein 1 (MCP-1) which attracts monocytes, and adhesion molecules which 
capture monocytes on endothelial cell membranes (Blankenberg, Barbaux, & 
Tiret, 2003; Bonow et al., 2011; Tedgui & Mallat, 1999). This assists the crossing 
of monocytes into the tunica intima where they are exposed to stimuli which 
initiate their differentiation into macrophages (Moore & Freeman, 2006). These 
macrophages are then stimulated to express scavenger receptors which bind to 
OxLDL-C and engulf them (Moore & Freeman, 2006). However, the 
macrophages that have engulfed OxLDL-C become ‘overwhelmed’ and instead of 
breaking down the lipids, they turn into foam cells which accumulate within the 
tunica intima, contributing to the development of atheroscleorsis (Suzuki, 
Kurihara, Takeya, & Kamada, 1997). Macrophages within the tunica intima that 
express scavenger receptors also display antigens from the OxLDL-C which 
attracts T cells (Hansson, 2001). In the centre of the mass these foam cells can 
undergo apoptosis where they deposit more LDL-C, this is termed the necrotic 
core (Ramji & Davies, 2015). At this stage, the fatty streak is formed, which is the 
first visible sign of atherosclerosis and health issues can begin to arise (Steinberg, 
2009). After this, smooth muscle cells (SMC) from the tunica media then divide 
into new SMCs which migrate into the tunica intima (Blankenberg et al., 2003; 
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Tedgui & Mallat, 1999). The SMCs continue dividing in the tunica intima, 
forming a fibrous cap with collagen, which allows the plaque to become 
stabilised, progressing from a fatty streak to a fibrofatty lesion (Blankenberg et 
al., 2003). The plaque contains a matrix made from SMCs which traps and 
accumulates foam cells and LDL-C. The matrix is then encased by a cap of SMCs 
and collagen. Once this is established, SMCs can undergo apoptosis which 
enables more LDL-C through the endothelium into the tunica intima (Blankenberg 
et al., 2003; Tedgui & Mallat, 1999). The established plaque narrows blood flow, 
and if the fibrous cap becomes damaged, thrombosis is likely to occur as the 
contents of the plaque spill out into the blood stream (Bentzon, Otsuka, Virmani, 
& Falk, 2014). Additional cholesterol from dietary choices can also increase the 
amount of circulating cholesterol (Graudal et al., 2012; Micha et al., 2010; Slinin 
et al., 2005). However, this alone is not likely to initiate atherosclerosis but can 








































































































































































































































































































































































































































































































In addition to LDL-C concentration, factors such as inflammation and immune 
response may also contribute to atherosclerosis. 
More recently, atherosclerosis is being viewed as a chronic inflammatory disorder 
(Hotamisligil, 2006). Cytokines released by macrophages and T cells have several 
modulatory effects on surrounding cells, and in atherosclerotic environments can 
alter endothelial cell function, SMC proliferation and thrombosis (Liao & Laufs, 
2005). Furthermore, inflammation has been suggested to have a role in the 
initiation and progression of atherosclerosis (Peter Libby, Ridker, & Maseri, 
2002). During initiation, inflammatory signals from selectins are involved in 
increasing the number of adhesion molecules on the endothelial cells, attracting 
more monocytes (Peter Libby et al., 2002). Throughout the subsequent 
progression of atherosclerosis, immune cells and surrounding cells such as SMCs 
within the forming plaque produce a range of chemokines, interleukins and 
cytokines (Peter Libby et al., 2002). These produce a pro-inflammatory 
environment and help uphold progression of the plaque (Ramji & Davies, 2015). 
There is evidence to suggest inflammation has a major role in the development of 
atherosclerosis, although its role in LDL-C oxidisation is still unknown (Peter 
Libby et al., 2002; Ramji & Davies, 2015).   
The role of immune cells in atherosclerosis is complimentary to inflammation. In 
the past, immune cells have been described only as a part of the plaque mass 
(Hansson & Libby, 2006). But more recently, immune cells, particularly 
macrophages, are seen as a main contributor to atherosclerosis which may have 
some role in initiation (Ramji & Davies, 2015). In the past, macrophages were 
thought to be the only immune cells involved in atherosclerosis. But it has now 
been discovered that macrophages attract T cells which also contribute to 
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atherosclerosis by promoting inflammation (Hansson, 2001; Hansson & Libby, 
2006). Macrophages attract T cells by presenting foreign antigens, which in this 
case is the negatively charged macromolecules on OxLDL-C which macrophages 
use scavenger receptors to identify (Hansson, 2001). This illustrates that both the 
innate and adaptive immunity have a role in atherosclerosis and more research 
needs to be done to uncover the extent of and reason for their contribution 
(Hansson & Libby, 2006; Peter Libby et al., 2002).  
Although the progression of atherosclerosis has been split into three hypotheses 
(oxidation of LDL-C, inflammation and immune response), the progression of 
atherosclerosis is likely to be a combination of all these. All three explanations are 
shown to play some role in atherosclerosis and have significant of overlap. This 
suggests the three hypotheses and their interactions with one another are likely the 
main drivers of atherosclerotic development (Galkina & Ley, 2009).  
While cholesterol may seem detrimental to health, it is an essential lipid which is 
crucial for the normal operation of cells (Goldstein & Brown, 2009). With proper 
function of cholesterol regulation in healthy individuals, atherosclerosis is not 
likely to occur.   
6.2.2 Cholesterol production and regulation 
Cholesterol is a vital lipid for several reasons. It is a main component of cell 
membranes which gives them their fluidity, is the precursor for many steroid 
hormones and has a significant role in the development of myelin sheaths around 
axons (Goldstein & Brown, 2009). Cholesterol needs to be transported in 
lipoproteins within the blood stream because it is hydrophobic. The purpose of 
LDL-C is to transport cholesterol from the liver where plenty is produced, to cells 
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within the body which require it. LDL-C is only one of the fractions of 
lipoproteins, with five others that are used to carry various lipids (Goldstein & 
Brown, 2009). High density lipoprotein cholesterol (HDL-C) is another key 
fraction which delays the progression of atherosclerosis as it collects cholesterol 
from the vascular system to be transported to the liver, converted to bile acids and 
excreted (Gordon et al., 1989; Sanossian, Saver, Navab, & Ovbiagele, 2007). The 
cholesterol is esterified during uptake by a LDL and once it reaches a cell which 
requires more cholesterol than it can produce, it is uptaken through receptor 
mediated endocytosis (Figure 2) (Maxfield & Wüstner, 2002) . However, the 
molecular structure of LDL-C makes it more susceptible to oxidation (Goldstein 
& Brown, 2009). Once the LDL-C is brought into the cell, lysozymes break down 
the lipoprotein, releasing the cholesterol. Cholesterol then has several regulatory 
effects within the cell, including reducing the amount of 3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase (HMGR) – a key enzyme for cholesterol 
production – and decreasing the number of LDL receptors which is controlled by 
sterol regulatory element-binding proteins (SREBPs). Cholesterol also causes an 
increase in acyl coenzyme A cholesterol acyltransferase (ACAT). These three 
regulatory steps ensure a negative feedback loop and maintain lipid homeostasis 
within cells (Goldstein & Brown, 2009). 
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SREBPs ensure the maintenance of lipid homeostasis within cells by increasing 
transcription of cholesterol producing enzymes during low cholesterol levels in 
cells (Michael S. Brown & Goldstein, 1999; DeBose-Boyd, 2008). SREBPs are 
located in the membrane of the endoplasmic reticulum (ER) and when released 
via two separate cleavages, have downstream effects which increase cholesterol 
production (Figure 3) (DeBose-Boyd, 2008). SREBP cleavage-activating protein 
(SCAP) is the cholesterol detecting protein located in the ER which binds to 
SREBPs in response to low cholesterol levels. The SCAP/SREBP complex 
migrates to the golgi body for proteolytic processing, where the first cleavage of 
SREBP by Site-1 protease (S1P) cuts the SREBP into two halves, both of which 
remain attached to the golgi body (DeBose-Boyd, 2008). Site-2 protease (S2P) 
then cuts one of the halves, the NH2-terminal bHLH-Zip domain (bHLH), from 
the golgi body membrane so it can bind to a sterol response element (SRE) in the 
Figure 2. LDL-C is brought into the cell via receptor mediated endocytosis. Once the LDL-C has 
been internalised, lysozymes are hypothesised to break down the amino acids releasing the free 
cholesterol. The release of cholesterol has several downstream effects on lipid homeostasis. 
Reprinted from “The LDL Receptor” by J. L. Goldstein and M. S. Brown, 2009, Atheroclesrosis, 





nucleus. In the nucleus, bHLH influences the transcription of cholesterol 
production target genes such as the HGMR and LDL-receptor gene (Shimano, 
2001). When there is a high concentration of cholesterol present, the binding of 
SCAP to another ER protein called insulin-induced gene 1 protein (INSIG-1) and 
insulin-induced gene 2 protein (INSIG-2) inhibits its binding to SREBP, therefore 
inhibiting the production of cholesterol (Michael S. Brown & Goldstein, 1999; 
Yabe, Brown, & Goldstein, 2002; Yang et al., 2002). HMGR, ACAT and LDL 
receptor are three key components of cholesterol regulation (DeBose-Boyd, 
2008).
HMGR is an enzyme which catalyses the rate limiting step in the mevalonate 
pathway, the conversion of HMG CoA to mevalonate (Buhaescu & Izzedine, 
2007). The mevalonate pathway is responsible for the production of cholesterol. 
Figure 3. The regulation of cholesterol production through the SREBP pathway. In the 
presence of cholesterol, SCAP binds to SREBP in the ER membrane. SCAP/SREBP then 
migrates to the golgi body where two cleavages are made. bHLH then binds to SRE in the 
nucleus., which influences the transcription of cholesterol related genes. Reprinted from 
“Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and 
degradation of HMG CoA reductase” by R. A. DeBose-Boyd, 2008, Cell Research, 18, p. 
609-621. Copyright 2008 by Nature Publishing Group. 
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Through multiple steps, acetyl-CoA is used to create desmosterol and 7-
dehydrocholestrol which together form cholesterol (Figure 4) (Buhaescu & 
Izzedine, 2007). When cholesterol concentrations are low in cells, SREBPs are 
activated which increases the transcription rate of HMGR (DeBose-Boyd, 2008). 
However, during high concentrations of cholesterol, SREBP activation is 
supressed as described above (DeBose-Boyd, 2008). With an abundance of 
cellular cholesterol, the degradation of HMGR is also increased up to three fold to 
further reduce cholesterol production (Gil, Faust, Chin, Goldstein, & Brown, 





ACAT is an enzyme which catalyses the reaction of cholesterol to cholesterol 
esters (Chang, Li, Chang, & Urano, 2009). When cholesterol is abundant in the 
cell, it directly activates ACAT to convert excess cholesterol into cholesterol ester 
Figure 4. A simplified schematic of the mevalonate pathway; the pathway responsible for 
cholesterol synthesis. Modified from “Advances in the physiological and pathological 
implications of cholesterol: Cholesterol in health and disease” by V. A. Cortes, D. Busso, P. 




to be stored as a reservoir (Goldstein & Brown, 2009). High levels of cholesterol 
ester in the blood stream can aid atherosclerosis because cholesterol ester transfer 
protein (CETP) exchanges cholesterol ester from HDL, for triglycerides in very 
low density lipoproteins (VLDL) (Okamoto et al., 2000). This can increase the 
amount of VLDL and LDL in the blood stream which contribute to 
atherosclerosis, and decrease the amount of circulating high density lipoprotein 
(HDL), which is crucial for cholesterol excretion (Okamoto et al., 2000).  
LDL receptors are produced in the rough ER and released into the cytoplasm 
where they undergo a conformational change before they can become active in the 
cell membrane (Goldstein & Brown, 1984). Like HMGR, when there are low 
concentrations of cholesterol in the cell, SREBPs can increase the transcription of 
LDL receptors (Goldstein & Brown, 2009). This controls the number of LDL 
receptors available to bring in exogenous cholesterol, preventing an over 
accumulation in the cell (Goldstein & Brown, 2009).  
However, when dysfunction does occur in these regulation mechanisms, statins 
can be used to manage cholesterol production and prevent the onset of CVD 
related adverse effects (Blaha & Martin, 2013). 
6.2.3 Molecular function of statins 
The benefits of statin use to decrease LDL-C is well debated in the literature, with 
overwhelming evidence showing that the overall health benefits of stains 
outweigh their side effects (Blaha & Martin, 2013; Di Sciascio et al., 2009; Koh, 
Sakuma, & Quon, 2011; Mihaylova et al., 2012; Stroes, 2005; Weng et al., 2010).   
Statins are able to lower LDL-C levels because they inhibit HMGR (Stroes, 
2005). At the active site of HMGR, 3-hydroxy-3-methylglutaryl-coenzyme A 
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(HMG-CoA) binds to the HMG-CoA-binding region, with nicotinamide adenine 
dinucleotide (NAD) also required to bind to the coenzyme-A-binding site for 
production of mevalonate (Friesen & Rodwell, 2004). Statins inhibit HMGR by 
binding to the HMG-CoA-binding region and blocking its access to HMG-CoA, 
due to their structural similarity (Figure 5) (Friesen & Rodwell, 2004; E. S. Istvan 
& J. Deisenhofer, 2001). Statins and HMG-CoA therefore compete against each 
other for access to the active site (E. S. Istvan & J. Deisenhofer, 2001). All statins 
inhibit HMGR by blocking its active site, however there are subtle differences in 
the way they bind due to their different molecular structures (Stroes, 2005).  The 
side chains of some statins have also been shown to block a portion of the 
coenzyme-A-binding site, having a higher efficiency for lowering LDL-C due to 
partial inhibition of coenzyme binding as well as HMG-CoA binding (Figure 5) 
(Friesen & Rodwell, 2004). Because HMGR is the rate limiting enzyme in the 
mevalonate pathway, targeting HMGR is effective for impeding the production of 
cholesterol from the liver and decreasing the amount of circulating LDL-C. With 
lower levels of cholesterol, expression of LDL-receptors on cells increases which 
removes LDL-C from the bloodstream without giving it a chance to contribute to 




Statins have also been observed to have other LDL-C reducing effects in addition 
to HMGR inhibition, such as a reduction in CETP activity (McTaggart & Jones, 
2008). Although statins are not thought to be direct inhibitors of CETP, some 
studies have suggested they may have some effect on CETP regulation (Guerin, 
Lassel, Le Goff, Farnier, & Chapman, 2000; McTaggart & Jones, 2008). CETP is 
a protein which exchanges cholesterol ester from HDL for triglycerides in VLDL 
as explained above. Guerin et al. (2000) suggest that atorvastatin, a type of statin, 
significantly decreases CETP plasma concentration, therefore decreasing the 





Figure 5. Molecular structure of six different statins depicting the hydroxyl group which 
binds to the HMG-CoA-binding region. The statins are able to compete with HMG-CoA for 
the HMG-CoA-binding region due to their structural similarity. Modified from 
“Biotransformation of waste biomass into high value biochemicals” by S. K. Brar, G. S. 
Dhillon & C. R. Soccol, 2014, New York, USA: Springer. Copyright 2014 by Springer 
Science and Business Media New York. 
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amount of cholesterol ester that is exchanged between HDL and VLDL. This 
increases the amount of HDL and decreases the amounts of VLDL and LDL in 
circulation. However, more research is required in this area of statin function and 
only a small number of statins such as atorvastatin have been shown to have this 
effect (McTaggart & Jones, 2008).   
In more recent research, statins have also been suggested to decrease the risk of 
CVD events independent of their influence on LDL-C. Studies have demonstrated 
a decrease in the risk of major cardiovascular events in people who have ‘normal’ 
LDL-C levels, as well as having an almost immediate effect on decreasing the 
incidence of heart attack after coronary revascularization surgery, irrespective of 
blood LDL-C concentration (Di Sciascio et al., 2009; Mihaylova et al., 2012).  
There are three potential reasons why statins decrease CVD risk irrespective of 
LDL-C. Firstly, when circulating levels of LDL-C are low, atherosclerotic plaques 
can still be present. Statin therapy may be able to reduce the size and therefore the 
risks associated with plaques (Makris, Lavida, Nicolaides, & Geroulakos, 2010; 
Tawakol et al., 2013; Vale et al., 2014). Secondly, statins may also be able to 
increase the amount of circulating HDL, therefore excreting more cholesterol by 
influencing CETP activity. Lastly, statins are hypothesised to have a non-
inflammatory influence which disrupts plaque formation, altering the ‘pro-
atherosclerotic’ environment (Antonopoulos, Margaritis, Lee, Channon, & 
Antoniades, 2012; Subramanian et al., 2013). This was supported by an observed 
decrease in the number of inflammatory cells within a plaque after statin therapy, 




Along with the health benefits statins come with, the use of some statins seem to 
propel behavioural changes which lead to increased BW, counterproductive for 
the treatment of underlying metabolic dysfunction statins (Aguirre et al., 2013; 
Athyros & Mikhailidis, 2014; Redberg, 2014; Sugiyama et al., 2014; Swerdlow et 
al, 2015). This counteracts the benefits statins have and can not only decrease the 




6.3 Increase of appetite and body weight by statin use  
The use of statins has been shown to increase BW and adiposity in several studies 
(Aguirre et al., 2013; Athyros & Mikhailidis, 2014; Redberg, 2014; Sugiyama, 
Tsugawa, Tseng, Kobayashi, & Shapiro, 2014; Swerdlow et al.). Sugiyama et al. 
(2014) demonstrated an increase in calorie and fat intake in adult humans after 
statin use, and showed statin users have a faster increase of body mass index 
(BMI) than non-statin users. The increase in BW has been shown in several 
different types of statins (Aguirre et al., 2013; Athyros & Mikhailidis, 2014; 
Redberg, 2014; Sugiyama et al., 2014; Swerdlow et al, 2015).(Aguirre et al., 2013; Athyros & Mikhailidis, 
2014; Redberg, 2014; Sugiyama et al., 2014; Swerdlow et al.).  
Swerdlow et al. (2015) demonstrated that single nucleotide polymorphisms 
(SNPs) in human DNA which effect the function of HMGR showed similar 
effects in BW increase when statins are taken in humans. This suggests that statins 
causing disruption to HMGR may be one of the contributors to an increase in BW 
(Swerdlow et al, 2015). (Swerdlow et al.).  
Statins have also been shown to cause a difference in body fat accumulation, with 
Aguirre et al. (2013) suggesting subcutaneous adipose tissue increases a 
significant amount after only six weeks of statin use in rat models.  
However, there are several different types of statins, and their differences can 
have alternative influences on physiology. Some physiological differences include 
variation in bioavailability, LDL-C and triglyceride lowering efficiency and their 
ability to increase HDL levels (Huffman, 2002; Schaefer et al., 2004). Some 
statins have also been suggested to cause changes in adipose development, with 
hydrophilic statins shown to be better at preventing lipid accumulation in 
particular areas of the body such as renal tubules when compared to lipophilic 
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statins (Gotoh et al., 2013). There are also differences in statin efficiency between 




6.4 Simvastatin  
There are several different types of statins with lovastatin, pravastatin, 
simvastatin, atorvastatin, pravastatin and fluvastatin being the main ones 
discussed in the literature (Jones, Kafonek, Laurora, & Hunninghake, 1998; 
Schaefer et al., 2004; Shepherd, Hunninghake, Barter, McKenney, & Hutchinson, 
2003). They all have subtle differences; lovastatin is a ‘natural’ drug synthesised 
from fungi, and pravastatin and simvastatin are slight variations from lovastatin; 
while atorvastatin, fluvastatin and rosuvastatin are made synthetically (Chong, 
Seeger, & Franklin, 2001; Schachter, 2005). There are also differences in their 
molecular properties where atorvastatin, lovastatin and simvastatin are lipophilic 
and pravastatin, rosuvastatin and fluvastatin are more hydrophilic (Gotoh et al., 
2013). Lipophilic statins are able to cross the blood brain barrier (BBB), which 
suggests they may potentially have an effect in the central nervous system (CNS).  
Simvastatin and lovastatin are also the only two statins which are not taken in 
their active state, making them (Istvan & Deisenhofer, 2001). They must first be 
hydrolysed when ingested to form the active hydroxyl acid which binds to the 
HMGR active site (Istvan & Deisenhofer, 2001). (Eva S Istvan & Johann Deisenhofer, 2001). 
Simvastatin has been classified as the second most effective statin at decreasing 
LDL-C after atorvastatin, however a larger number of mild adverse side effects 
have been identified by patients using atorvastatin such as nausea, myalgia and 
joint pain (Schaefer et al., 2004; Wierzbicki et al., 1999). Because atorvastatin is 
most effective it is the most commonly prescribed statin in New Zealand with 
8.9% (284,262) of the population taking atorvastatin, and 7.1% (226,984) of the 
population taking simvastatin (Best Practice Advocate Centre New Zealand, 
2014). (bpacnz, 2014). 
23 
 
Although simvastatin has been found as a safe long term treatment for CVD, a 
few papers have shown that simvastatin increases food intake (FI) and BW (Carr, 
2014; Palus et al., 2013). Majority of research papers show conflicting results, 
arguing that simvastatin use causes a decrease BW (Mansouri, Khodayar, 
Tabatabaee, Ghorbanzadeh, & Naghizadeh, 2015; Reinehr & Andler, 2004). 
However, it has been suggested that research showing a decrease in FI and BW 
induced by simvastatin is flawed because simvastatin possibly has an effect on 
energy expenditure (EE) (Cleanthous et al., 2011; Derosa, Mugellini, Ciccarelli, 
Rinaldi, & Fogari, 2002; Khan, Hamilton, Mundy, Chua, & Scherer, 2009; 
Kretzer, Maria, Guido, Contente, & Maranhão, 2016). An increased EE suggests 
that if control and treatment animals are being fed the same amount of food, 
treatment animals would lose BW due to an increased metabolism (Khan et al., 
2009). Majority of research has also shown that simvastatin inhibits adipogenesis 
in vitro, however Khan et al. (2009) suggested that during in vivo studies, 
simvastatin may increase the differentiation of adipocytes (Mäuser, Perwitz, 
Meier, Fasshauer, & Klein, 2007; Nishio, Tomiyama, Nakata, & Watanabe, 1996; 
Song et al., 2003; Tomiyama, Nishio, & Watanabe, 2001). This demonstrates the 
difference between in vivo and in vitro research, where there may be pleiotropic 
effects in vivo that in vitro studies cannot detect. Although there is still debate in 
the literature, recent research is skewed towards simvastatin increasing BW and 
perhaps adiposity, and explanations for potentially incorrect opposing findings are 
being uncovered (Carr, 2014; Cleanthous et al., 2011; Khan et al., 2009; Kretzer 
et al., 2016; Palus et al., 2013). It is still unclear what is causing this change in FI 
and EE, and little research has been done on the mechanisms behind an observed 
increase in BW by simvastatin use. Because simvastatin is a lipophilic statin and 
24 
 
is able to cross the BBB, it could potentially have both a peripheral effect, which 




6.5   Peripheral vs central mechanisms effecting food intake 
FI has both peripheral and central influences and is defined as the amount of food 
ingested within a given time period (Lenard & Berthoud, 2008). The regulation of 
FI along with EE are main components determining BW.  
6.5.1 Peripheral regulation of food intake 
The peripheral regulation of FI includes gastrointestinal information from 
mechanical and hormonal signalling. Gastrointestinal mechanoreceptors play a 
role in satiety and controls meal size and frequency (Cummings & Overduin, 
2007; Houpt, 1982). During a meal, gastric distension triggers mechanoreceptors 
to send sensory information to the brain. These regions are then able to use 
neuronal pathways to secrete hormones causing a decrease in FI. The gut itself 
also has enteroendocrine cells which secrete gut peptides when food is ingested. 
This decreases appetite and increases satiety, therefore concluding meal time 
(Cummings & Overduin, 2007; Houpt, 1982). Such gut peptides include 
cholecystokinin (CCK), glucagon-like peptide-1(GLP-1) and peptide YY (PYY) 
(Cummings & Overduin, 2007; Houpt, 1982; Lenard & Berthoud, 2008). There 
are also hormones which control the increase of appetite when meal times are 
approaching, which is the role of a hormone called ghrelin (Klok, Jakobsdottir, & 
Drent, 2007). Ghrelin is secreted by the gastrointestinal system when the stomach 
is empty, eliciting hunger and promoting fat storage. Secretion is stopped once the 
stomach becomes stretched, which shows ghrelin plays a key role in meal 
initiation (Klok et al., 2007).  
Leptin is another hormone involved in peripheral FI regulation and is secreted by 
adipose tissue. Leptin is able to cross the BBB and effect the hypothalamus, 
decreasing FI and increasing EE as fat reserves become higher (Klok et al., 2007). 
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Leptins role has been described as an intended pathway to prevent obesity, as 
more adipose tissue accumulates, more leptin is secreted to decrease FI. However, 
long term exposure to high leptin levels decreases its effectiveness due to 
decreased abundance in leptin receptors (Halaas et al., 1997). Leptin is also a key 
component in central regulation by binding to leptin receptors within the 
hypothalamus (Hayes et al., 2010).  
The adrenal gland has also been shown to secrete hormones, such as cortisol, 
which effect FI. Cortisol is a steroid hormone which is most commonly associated 
with the stress response elicited by the hypothalamic-pituitary-adrenal (HPA) axis 
(George, Khan, Briggs, & Abelson, 2010). Cortisol has been suggested to increase 
FI during the short initial stages of the stress responses, with long term stress 
causing a decrease in appetite (Appelhans, Pagoto, Peters, & Spring, 2010; 
George et al., 2010).  
Insulin is secreted by the pancreas in response to high blood glucose levels, and is 
able to reduce FI by crossing the BBB and binding to insulin receptors in the 
hypothalamus, similarly to leptin (Schwartz, Woods, Porte, Seeley, & Baskin, 
2000). Insulin has also been shown to have an effect on EE by influencing fat 
deposition (Schwartz et al., 2000).  
It is noteworthy to mention that although these mechanisms take place in the 
periphery, the periphery is not a closed circuit. The periphery sends sensory 
information to the CNS which propagates FI responses.   
6.5.2 Central regulation of food intake  
Central regulation is the overarching control mechanism of FI regulation, with 
three main areas of the brain responsible; the cortico-limbic, caudal brainstem and 
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hypothalamic systems (Figure 6) (Lenard & Berthoud, 2008). Neural pathways 
and molecules in these areas have roles in both eating for pleasure and energy, 
however, the cortico-limbic system is more associated with eating for pleasure, 
while neural pathways and molecules in the caudal brain stem and hypothalamus, 
in the context of this study, are more associated with eating for energy. 
 
6.5.2.1 Central regulation of food intake for pleasure 
Cortico-limbic systems in this context are involved in reward circuits which 
encourage the intake of palatable food. Some of the areas involved in this 
response are the nucleus accumbens (NAc), ventral pallidum (VP) and ventral 
tegmental area (VTA). The main drivers of food hedonics are opioids, dopamine 
and serotonin (Lenard & Berthoud, 2008).  
The ingestion of palatable foods regardless of hunger was an evolutionary benefit 
because foods high in sugars and fats are required for normal physiological 
Figure 6. Simplified schematic of the three brain systems associated with the control of food 
intake and energy expenditure; cortico-limbic, caudal brainstem and hypothalamic regions. 
Reprinted from “Central and Peripheral Regulation of Food Intake and Physical Activity: 
Pathways and Genes” by N. R. Lenard & H. Bethoud, 2008, Obesity, 16(S3), p. S11-S22. 
Copyright 2008 by John Wiley and Sons.   
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function (Mela, 2006). These foods were usually rare, so when they were found, 
consuming them in high amounts was beneficial for survival (Mela, 2006). 
However, in our current obesogenic environment, eating for pleasure is no longer 
important for survival and promotes weight gain (Lenard & Berthoud, 2008). 
There are three systems which drive hedonic eating; opioids, dopamine and 
serotonin systems.  
Opioids are a family of peptides including endorphins, enkephalins and 
dynorphins (Kelley et al., 2002). Opioids are important in the neurophysiology of 
addiction, and it is a well-supported hypothesis that opioids increase hedonic FI, 
although the exact mechanisms remain undetermined (Berridge, 1996; Calcagnetti 
& Reid, 1983; Kelley et al., 2002; Saper, Chou, & Elmquist, 2002). Studies have 
demonstrated that opioid drugs such as morphine increase hedonic FI while 
naloxone, a drug used to block opioid receptors, reduces the preference for 
palatable foods (Frenk & Rogers, 1979). The NAc is thought to have a key role in 
this pathway because it has a high abundance of opioid receptors, and was 
therefore used to gain information on opioid receptor potency (Trezza, Damsteegt, 
Achterberg, & Vanderschuren, 2011). It was discovered that mu-opioid receptors, 
one of the three opioid receptor types, was most potent at inducing hedonic eating. 
Therefore opioids with high affinity for these receptors (enkephalins and beta-
endorphin) have the most effect on hedonic FI (Trezza et al., 2011). However, the 
ventral striatum has been labelled as a key brain region for opioid control of 
hedonic eating, which has been shown to regulate desirability of palatable foods 
in order to increase FI (Kelley et al., 2002; Saper et al., 2002).  
The dopamine system has been more difficult to relate to hedonic eating 
regulation. Dopamine neurons within the NAc are involved in addiction similarly 
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to opioid receptors, and therefore were hypothesised to be involved in hedonic 
eating also (Saper et al., 2002). However, early studies where the NAc was 
damaged but hedonic eating still occurred suggested dopamine did not have a key 
role in hedonic eating regulation (Balleine & Killcross, 1994). Furthermore, the 
inability to produce dopamine in mice caused them to die from starvation which 
could be reversed by administration of tyrosine hydroxylase, the rate limiting 
enzyme for biosynthesis of dopamine (Szczypka et al., 2001). It is now widely 
accepted that both dopamine and the NAc have some role in hedonic eating 
regulation, however the system is much more complex than being isolated to only 
a few molecules in these brain regions, making it difficult to study. It has been 
suggested that although dopamine is expressed during exposure to rewarding 
stimuli, dopamine release is highest after initial exposure to novel reward (Hajnal 
& Norgren, 2001). As a reward food item becomes more familiar, less dopamine 
is released having a smaller effect on hedonic FI (Hajnal & Norgren, 2001; 
Schultz, 1998). Perhaps this is why damage to the NAc was observed to have no 
effect on hedonic eating during studies because it is not essential for hedonic 
eating to occur, suggesting the relationship between dopamine and hedonic 
reward is more complicated than what was initially assumed (Saper et al., 2002).   
Serotonin has also been shown to have an effect on both eating for energy and 
pleasure, however this system is much less studied than the opioid and dopamine 
systems (Saper et al., 2002). Serotonin has been shown to modulate FI regulation 
by increasing activation of POMC/CART neurons within the ARC, causing a 
decrease in FI for energy (Meguid et al., 2000; Saper et al., 2002). However, 
serotonin also stimulates POMC/CART neurons to produce beta-endorphin 
(Heisler et al., 2002; Kelley et al., 2002; Saper et al., 2002). Beta-endorphin binds 
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to mu-opioid receptors, the most potent receptor for inducing hedonic FI, 
modulating the initiation of the reward response (Heisler et al., 2002; Kelley et al., 
2002; Saper et al., 2002). Serotonin has also been shown to decrease the 
preference for high fat and high sugar diets, even though their presence in the 
hypothalamus increases beta-endorphin levels (Blundell, Lawton, & Halford, 
1995; Flaherty, Turovsky, & Krauss, 1994).  Although current research points 
towards serotonin having an overall decrease in FI both for energy and pleasure, 
there are still conflicting results of what serotonins role is in hedonic eating and 
more research needs to be done to confirm this role (Heisler et al., 2002; Meguid 
et al., 2000; Saper et al., 2002).  
However, eating for pleasure is only one of the forms of central regulation of FI. 
The CNS also has a crucial role in the regulation of eating for energy through 
neural pathways and molecules within brain regions such as the caudal brainstem 
and hypothalamus. 
6.5.2.2 Central regulation of food intake for energy 
Areas within the brainstem have a role in appetite regulation. This includes the 
nucleus of solitary tract (NTS), area postrema (AP) and dorsal motor nucleus of 
the vagus nerve (DMNV). NTS and AP both have leptin receptors, which when 
activated cause a decrease in FI (Hayes et al., 2010). The NTS is also integrated 
into the neural pathways of hypothalamic regions such as the lateral hypothalamic 
area (LHA), which has a key role in food intake for energy (Hayes et al., 2010). 
Because the AP is located outside the BBB, it has the unique ability it respond to 
peripheral hormones which are not able to cross the BBB such as CCK and GLP-1 
(Saper et al., 2002). The DMNV receives information from the periphery via the 
vagus nerve to decrease FI, and has also been shown to decrease FI through the 
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binding of melanocortin’s such as α-melanocyte-stimulating hormone (α-MSH) to 
melanocortin 4 receptor (MC4-R) (Williams, Kaplan, & Grill, 2000). This 
suggests the DMNV is able to effect FI without any input from the vagal nerve 
(Williams et al., 2000). Although the brainstem has a key role in appetite 
regulation and relaying information, the hypothalamus has been labelled as 
another brain region whose neural pathways and molecules are crucial for FI and 
EE regulation.  
Neural pathways and molecules associated with the hypothalamus integrate 
information from the periphery and stimulate the pituitary gland to release 
hormones which impact FI. This includes the neural pathways and molecules 
associated with several brain regions including the supraoptic nuclei (SOP), 
dorsomedial hypothalamic nucleus (DMH), ventromedial nucleus of 
hypothalamus (VMH), arcuate nuclei (ARC), LHA and paraventricular nuclei 
(PVN). 
The SOP has projections into the posterior pituitary gland which transports 
vasopressin and oxytocin for release into the bloodstream (Jezova, Michajlovskij, 
Kvetnansky, & Makara, 1993). Projections from the PVN are also able to do this 
(Jezova et al., 1993). Activation of DHN causes a decrease in FI, and BW as well 
as a decrease in thirst (Bellinger & Bernardis, 2002). VMH has a role in satiety, 
where electrical stimulation has been shown to decrease FI (Bellinger & 
Bernardis, 2002). LHA has been termed a key brain area for the regulation of 
hunger, as stimulation of the LHA increases FI as well as water consumption 
(Stuber & Wise, 2016). The LHA uses two hormones, orexin and melanin 
concentrating hormone (MCH) to create changes in FI regulation. It has also been 
suggested to have a key role in the reward system where orexin fibres are able to 
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innervate dopamine neurons within the VTA (Berthoud & Münzberg, 2011; Saper 
et al., 2002; Stuber & Wise, 2016). The ARC is a key brain region associated with 
the regulation of appetite, containing two populations of neurons which have been 
associated with either an increase or decrease in FI, depending on the presence of 
effector molecules such as leptin or insulin (Katherine A Simpson, Martin, & 
Bloom, 2008). In the context of eating for energy, a more thorough discussion of 
the ARC, PVN and LHA is warranted due to their crucial roles in central 
regulation on FI.      
In the ARC, there are two key populations of neurons; neuropeptide Y/ agouti-
related protein (NPY/AgRP) and pro-opiomelanocortin/ cocaine- and 
amphetamine-regulated transcript (POMC/CART) neurons (Cone, 1999). Both 
have receptors which bind leptin and insulin. With a high concentration of leptin/ 
insulin, NYP/AgRP inhibition and POMC/CART excitation have a anorexigenic 
effect (decreases FI). In contrast, low concentration of leptin/ insulin, NYP/AgRP 
excitation and POMC/CART inhibition has an orexigenic effect (increases FI) as 
well as an increase in fat deposition (Figure 7) (Cone, 1999). Leptin and insulin 
can cross the BBB and are found at the same concentration in blood plasma as 
they are in cerebral spinal fluid (CSF) (Cone, 2005; Oswal & Yeo, 2007). Leptin’s 
effects in the ARC have also been shown to influence glucose metabolism and 
locomotor activity as well as FI (Coppari et al., 2005). POMC/CART neurons are 
able to effect FI because POMC is cleaved to produce melanocortin’s such as α-
MSH, which bind to MC4-Rs in the PVN, decreasing FI (Arora, 2006). The 
release of AgRP has been shown to block the binding of α-MSH to MC4-R in the 
PVN as a secondary regulation mechanism when NPY/ AgRP neurons are active 
(Schwartz et al., 2000). These MC4-R receptors have been found in more places 
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throughout the brain, which have an effect on eating control such as the NAc 
which then innervates to the LHA (Saper et al., 2002). CART is usually co-
expressed with POMC and shows anorexigenic effects when administered directly 
into the hypothalamus (Lau & Herzog, 2014). However, CART administered ICV 
has been shown to have orexigenic effects demonstrating CART may have several 



































































































































































































































































































































During a lack of leptin, when NYP/AgRP neurons are activated along with AgRP 
blocking the binding of α-MSH to MC4R, it also causes production of y-
aminobutyric acid (GABA) which inhibits POMC neurons from decreasing FI 
(Lenard & Berthoud, 2008). NPY then binds to neuropeptide Y receptors type 1 
(Y1) and neuropeptide Y receptors type 5 (Y5) in the PVN (these receptors are 
also found in the DMN and VMH), causing an increase in FI (Kalra, Dube, Sahu, 
Phelps, & Kalra, 1991; Nguyen et al., 2012; Schwartz et al., 2000).  
The groups of neurons in the ARC can also be effected by ghrelin and PYY. 
Ghrelin has been shown to activate neurons in the ARC to stimulate appetite, 
however, ghrelin has not been shown to cross the BBB (Cowley et al., 2003). 
Despite this, small populations of specialised cells in the brain are able to secrete 
the ghrelin which effects the central regulation of FI. The effect and importance of 
ghrelin in the brain is much less studied than the effect of peripheral ghrelin 
(Cowley et al., 2003). PYY is secreted from L-cells in the intestine to decrease FI, 
however PYY can cross the BBB binding to Y2 receptors in the ARC, inhibiting 
NPY/AgRP neurons and can stimulate POMC/CART neurons (Karra, 
Chandarana, & Batterham, 2009; Le Roux & Bloom, 2005). NPY/AgRP and 
POMC/CART neurons in the ARC project to other brain regions such as PVN, 
LHA and DHN where they can elicit their responses (Katherine Anne Simpson, 
Martin, & R Bloom, 2009).  
There are two main cell groups in the PVN; parvocellular and magnocellular 
sections (Hill, 2012) . Parvocellular neurons transport neuropeptides to the median 
eminence which initiate the production of hormones from the anterior pituitary. In 
the anterior pituitary, stimulatory hormones such as corticotropin-releasing 
hormone (CRH) and thyrotropin-releasing hormone (TRH) cause the release of 
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effector hormones into the blood stream. These effector hormones include 
adrenocorticotropic hormone (ACTH) which controls the adrenal axis and 
thyrotropin-stimulating hormone (TSH) which controls the thyroid axis, as well as 
dopamine which control the reproduction axes and somatostatin which controls 
growth and development (Geerling, Shin, Chimenti, & Loewy, 2010; Hill, 2012). 
The whole pathway from innervation of ARC neurons by peripheral stimuli, to 
release of hormones from the pituitary gland is one of the ways FI and EE is 
regulated. Using the thyroid axis as an example of this pathway, when leptin 
levels are high and NPY/AgRP neurons are activated, this sends a signal to the 
PVN to release TRH (Figure 8) (Nillni, 2010). Parvocellular neurons transfer the 
signal elicited by TRH to the anterior pituitary where TSH is produced and 
released into the bloodstream. TSH will then stimulate the thyroid gland to 
produce hormones triiodothyronine (T3) and thyroxine (T4) which increase 






















The adrenal axis has a similar process, where NPY/AgRP neurons release CRH 
from the PVN, which in turn stimulates ACTH from the anterior pituitary. This 
stimulates the adrenal gland to release cortisol into the blood stream initiating the 
stress response and overall decreasing FI (Kohno et al., 2008). All the separate 
axes contribute to an overall increase or decrease in FI depending on the signals 
given from the periphery and brain regions. These axes can also reiterate the 
complexity of the central regulation on FI. The hormones released into the blood 
Figure 8. Hypothalamic-pituitary-thyroid axis showing the central pathway leading to increased 
metabolism and the negative feedback loop of T3 and T4 on TRhH release. Modified from 
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Release of TSH into blood 
stream   
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stream such as ACTH and TSH have more functions than only influencing FI, 
which makes it difficult to narrow their involvement down to only one aspect of 
the wide range of roles they are involved in. For example, although TSH elicits an 
increase in EE, it also has a key role in brain maturation and growth (Glass et al., 
1987). The magnitude of connectivity makes dissecting out one function of a 
hormone or neuron problematic. This can have implications on the results of 
studies, because observations that are unable to be explained, or that are not 
consistent, may be due to pleiotropic effects these hormones and neurons have.  
 The magnocellular neurons act as a control centre for endocrine functions. These 
neurons along with neurons from the SON project to the posterior pituitary gland 
where they can either release vasopressin or oxytocin into the blood stream 
(Schwartz et al., 2000). Oxytocin has many roles once it is released related to 
lactation, parturition and bonding (Schwartz et al., 2000). However, its release 
from the pituitary has also shown downstream effects decreasing FI, and it has 
been suggested that AgRP is able to inhibit the release of oxytocin (Atasoy, 
Betley, Su, & Sternson, 2012). Vasopressin targets the kidneys for short or long 
term increases in water retention by the regulation of aquaporins, and increases 
thirst (Knepper, 1997). Meyer, Langhans, and Scharrer (1989) suggested 
vasopressin also decreases FI, however this has not been able to be replicated in 
following studies (Gulati & Sharma, 1993; Racotta, Soto-Mora, Palacios, & 
Quevedo, 1995).  
The LHA facilitates a second common central pathway for energy regulation 
which is the orexin and MCH pathway. Orexins release causes an increase in FI 
(Tsujino & Sakurai, 2013; Yamanaka et al., 2000). Therefore, high concentrations 
of leptin or glucose hyperpolarise orexin neurons making it more difficult for 
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them to produce action potentials, while low levels of glucose and ghrelin 
depolarise orexin neurons making it easier to produce action potentials (Tsujino & 
Sakurai, 2013; Yamanaka et al., 2000). There are two types of orexin; orexin-A 
and orexin-B. There are also two orexin receptors; orexin-1 and orexin-2 receptors 
(Rodgers, Ishii, Halford, & Blundell, 2002). Orexin-A binds to both receptors, 
while orexin-B binds mostly to orexin-2 receptor (Sakurai et al., 1998). Orexin-A 
has the most influence on FI with much less evidence supporting any role of 
orexin-B in FI regulation (Sakurai et al., 1998). Orexin has been shown to project 
to NYP/AgRP neurons to cause an increase in FI through the melanocortin 
pathway (Rodgers et al., 2002). However, POMC/CART neurons from the ARC 
also have projections which connect to the orexin neurons in the LHA, showing 
the relationships between orexins and the melanocortin pathway is complicated 
including several different, parallel pathways (Saper et al., 2002; Volkoff & Peter, 
2000). Orexins are also implicated in the reward system with projections to 
dopamine neurons within the VTA and serotonin neurons within the dorsal raphe 
nucleus (Rodgers et al., 2002). Orexin increases metabolism and EE which seems 
to be controlled by binding to orexin-2 receptor (Barson, Morganstern, & 
Leibowitz, 2013). Because orexin can affect the melanocortin pathway and is able 
to respond to peripheral signals such as leptin, glucose and ghrelin, it suggested 
orexins role is in food seeking and promoting FI, especially if it is palatable 
(Barson et al., 2013). Perhaps this suggests orexin has some role in the initiation 
of FI during meal times as well as more long term effects on energy metabolism 
and food preference (Barson et al., 2013). MCH is the other hormone within the 
LHA and also causes an increase in FI (Tritos et al., 1998). There are two MCH 
receptors; melanin-concentrating hormone 1 (MCH-1) and melanin-concentrating 
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hormone 2 (MCH-2) receptors. MCH-1 has been shown to play a key role in 
increasing FI which is separate from the melanocortin pathway (Shearman et al., 
2003). There is substantial evidence to show that MCH increases FI, and also 
increases energy conservation suggesting MCH has a role in reinforcing food 
consumption and ongoing FI (Barson et al., 2013). However, much less is known 
about the biochemical interactions MCH has with other neuropeptides and how it 
causes these changes (Barson et al., 2013). 
Both orexins and MCH increases FI with differing effects on EE. They have been 
observed to have an effect both on eating for pleasure and energy, although their 
degree of importance in these regulatory systems are unknown. However, LHA 
neurons are projected into several areas in the brain other than the hypothalamus 
and therefore the effect, purpose and function of orexin and MCH in the LHA are 
likely diverse. This may explain why their biochemical pathways are still largely 
unknown.  
Though there are both peripheral and central mechanisms responsible for 
controlling FI regulation, neither systems would be able to function in isolation. 
Cross talk between the periphery and CNS is crucial for the proper regulation of 
homeostasis (Figure 9). However, the CNS is the overarching regulation 





Eating for pleasure and for eating for energy are now thought to be two 
intertwined processes, where the same brain regions, neurons and molecules are 
able to influence both eating for pleasure and energy (Saper et al., 2002). There 
are many examples of this interlink, for example, leptin is one of the main 
Figure 9. The regulation of food intake and energy expenditure is controlled by both 
peripheral and central mechanisms. There is a lot of complexity between these two systems 
which are often referred to as separate systems when cross talk between these systems ensures 
proper functioning of homeostasis. Reprinted from “Pharmacotherapy of obesity: targets and 
perspectives” by A. Chiesi, C. Huppertz & K. G. Hofbauer, 2001, Cell press, 22(5), p. 247-
254. Copyright 2017 by Elsevier Science Ltd.  
42 
 
hormones used for regulating eating for energy. However, it has also been 
demonstrated to inhibit sweet taste cells on the tongue, influencing hedonic 
regulation at the most peripheral level (Saper et al., 2002). Another example is 
how POMC/CART neurons are crucial for the proper functioning of the 
melanocortin pathway, but also have the ability to produce beta-endorphin. 
Although they can be split apart and explained in isolation, it is significant to note 
that these systems function in conjunction with one another which adds more 




6.6 Rationale and aims 
There are many unknowns in the literature about central biochemical pathways 
which effect FI and EE, but the role of simvastatin on FI and EE has never before 
been explored. The goal of this research was to determine if simvastatin was 
causing an increase in FI in rat models, and to understand whether the 
mechanisms behind this increase was due to peripheral or central influences. This 
gains insight into the biochemical pathways involved. The three research aims 
which helped answer this goal were: 1. Determine the difference in energy driven 
FI between rats treated with simvastatin and controls (experiments one and two), 
2. Determine the difference in pleasure driven FI between rats treated with 
simvastatin and controls (experiment three), and 3. Determine whether FI 
differences are driven by eating for energy or pleasure supported by both FI and c-
Fos data (experiments one, two and five). These were achieved by doing a range 
of food intake studies as well as brain activation c-Fos immunoreactivity studies. 
FI for energy was investigated by looking at the differences in chow intake 
between deprived and non-deprived simvastatin and control groups. FI for 
pleasure was investigated by identifying diets preferred by rats administered with 
simvastatin, and by studying c-Fos activation in rat brains. During the study, 
water intake was measured. With the findings from this research, I hope to get a 
step closer to the development of statins which have less counterproductive side 





6.7 Materials and methods 
6.7.1 Animals 
The experiments were performed on 12-week-old male Sprague Dawley rats, 
single housed in standard plastic cages with wire lids, which were cleaned weekly. 
They were kept in a temperature- (22 ± 1 °C) and humidity-controlled room with 
a 12:12 light:dark cycle (lights on at 07:00). The animals had unrestricted access 
to food (Sharpes Feed) and tap water unless stated otherwise as part of 
experimental procedure. All experiments had approval from the University of 
Waikato Ethics Committee.  
6.7.2 Cannulation 
Animals were anaesthetised using ketamine (64.29 mg/mL) and xylazine 
(7.15mg/mL). A cannula was implanted stereotaxically in all rats for injection of 
simvastatin or DMSO into a lateral cerebral ventricle. With the rat's head in a 
stereotaxic frame, a hole was drilled into the skull, 1.6 mm lateral and 0.6 mm 
caudal to bregma, and a 22-gauge ICV guide cannula lowered with its tip 3.5 mm 
below the skull surface. The cannula was then fixed in place with dental acrylic 
and three small screws secured in the skull. Injections were given via a 28-gauge 
cannula, with its tip 1 mm below the guide cannula tip, connected via polythene 
tubing to a microsyringe. Animals were allowed one week to recover before being 
used in experiments.  
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6.8 Experiment design and analysis: Food intake  
6.8.1 Experiment one: Effect of Simvastatin on deprivation induced chow 
intake.  
20 male Sprague Dawley rats, of similar age and BW, were divided into four 
groups of five rats. The animals were deprived of food for 12 hours and then 
given ICV injections between 10:00 and 11:00. The control group was given a 3µl 
ICV infusion of 100% dimethyl sulfoxide (DMSO). The remaining three groups 
were given a 3µl ICV infusion of either 10, 30 or 100 nmol simvastatin, using 
DMSO as a vehicle. All animals had free access to food immediately after ICV 
infusion and food consumption was measured one, two and four hours after ICV 
infusion. All data was corrected for animal BW, and statistical analysis of the data 
comprised of a one-way ANOVA followed by the Fisher least significance test. 
P values <0.05 were considered significantly different. All statistical analysis was 
done using DeltaGraph software.  
6.8.2 Experiment two: Effect of Simvastatin on overnight chow intake  
20 male Sprague Dawley rats, of similar age and BW, were divided into two 
groups of ten rats. The control group was given a 3µl ICV infusion of DMSO, and 
the treatment group was given a 3µl ICV infusion of 30 nmol simvastatin (lowest 
effective dose) using DMSO as a vehicle, between 18:00 and 19:00. All animals 
had free access to food and food consumption was measured one, two, three, four, 
six and 12 hours after ICV infusion. All data was corrected for animal BW, and 
statistical analysis of the data included a student’s t test. P values <0.05 were 




6.8.3 Experiment three: Effect of Simvastatin on deprivation induced 
palatable food intake 
20 male Sprague Dawley rats, of similar age and BW, were divided into two 
groups of ten rats. The control group was given a 3µl ICV infusion of DMSO, and 
the treatment group was given a 3µl ICV infusion of 30 nmol simvastatin using 
DMSO as a vehicle, between 10:00 and 11:00. All animals were then given access 
to either 20% sucrose solution, 0.2% saccharin solution or sweetened milk (26% 
milk powder (Dairy Goat Co-operative skim milk powder) and 10% sucrose) 
following infusion, in three separate experiments, and liquid consumption was 
recorded after two hours. All data was corrected for animal BW, and statistical 
analysis of the data included a student’s t test. P values <0.05 were considered 
significantly different. All statistical analysis was done using DeltaGraph 
software. 
6.8.4 Experiment four: Effect of Simvastatin on deprivation induced water 
consumption 
20 male Sprague Dawley rats, of similar age and BW, were divided into two 
groups of ten rats. The animals were deprived of water for 12 hours and then 
given ICV injections between 10:00 and 11:00. The control group was given a 3µl 
ICV infusion of DMSO, and the treatment group was given a 3µl ICV infusion of 
30 nmol simvastatin using DMSO as a vehicle. All animals then had free access to 
water and water consumption was measured two hours after ICV infusion. All 
data was corrected for animal BW, and statistical analysis of the data included a 
student’s t test. P values <0.05 were considered significantly different. All 
statistical analysis was done using DeltaGraph software. 
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6.9 Experiment design and analysis: Brain activity 
6.9.1 Experiment five: Effect of simvastatin on c-Fos immunoreactivity 
20 male Sprague Dawley rats, of similar age and BW, were divided into two 
groups of ten rats. The control group was given a 3µl ICV infusion of DMSO, and 
the treatment group was given a 3µl ICV infusion of 30 nmol simvastatin using 
DMSO as a vehicle, between 10:00 and 11:00. Prior to the study, rats had free 
access to food and water. 
6.9.2 Euthanasia and perfusion 
Between 60 and 90 minutes after ICV infusion animals were deeply anaesthetised 
with an intraperitoneal injection of 3mL 35% urethane. They were then perfused 
with 100 ml of saline followed by 500 ml of 4% paraformaldehyde (PFA) in 
0.1 M phosphate buffer (pH 7.4). Brains were excised and postfixed overnight in 
PFA at 4 °C. 
6.9.3 Immunohistochemistry 
We studied the density of c-Fos immunoreactivity nuclei on nine brain sites 
involved in food intake: PVN, SOP, DMH, VMH, ARC, LHA, NTS, DMNV and 
AP. 
Coronal sections of 60 μm were cut on the Vibratome (Leica). They were 
processed as free-floating sections for standard immunohistostaining against c-
Fos. The tissue was treated for 10 min in 3% H2O2 in 10% methanol (in TBS, pH 
7.4–7.6) and incubated overnight at 4 °C in the rabbit anti-c-
Fos antibody (1:15000; Synaptic Systems). Subsequently, sections were incubated 
for one hour at room temperature in the goat-anti-rabbit antibody (1:400, Vector 
Laboratories), and then in the avidin-biotin complex (1:400; Vector Laboratories) 
for an hour. Peroxidase was visualised with a 15 minute incubation in 0.05% 
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diaminobenzidine, 0.01 H2O2, and 0.2% nickel sulfate. All incubations were done 
in a mixture of 0.25% gelatin (Sigma) and 0.5% Triton X-100 (Sigma) in TBS. 
Intermediate rinsing was done four times with TBS. Sections were mounted on 
gelatinised slides, dried, dehydrated in ascending concentrations of ethanol, 
soaked in xylene, and embedded in Entellan. 
The number of Fos positive nuclear profiles in the regions of interest was counted 
on 4–5 sections per animal using Scion Image software. Densities of Fos 
immunoreactivity nuclei (per mm2) were averaged per rat and then per group. The 
effect of simvastatin versus DMSO on c-Fos immunoreactivity was established 
with ANOVA followed by the Fisher least significance test. Values were 
considered significantly different when P < 0.05. All statistical analysis was done 





6.10.1 Experiment one: Effect of Simvastatin on deprivation induced chow 
intake 
The group of animals administered with 10nmol simvastatin ate less than the 
control group in every time bracket, while the group of animals administered with 
30nmol of simvastatin ate more than controls in every time bracket (Figure 10). 
The group of animals administered with 100nmol simvastatin had varied results, 
eating less than the control group during the 0-1 hour time bracket but eating more 
than the control group in the two following time brackets. 
There was a significant difference in the amount of chow eaten between the 
control group and the animals administered 30nmol simvastatin two hours after 
injection. There was also a significant difference in the amount of chow eaten 
between the control group and both the animals groups administered 30nmol and 
100nmol simvastatin 4 hours after injection.  
Injecting simvastatin at three different doses revealed the lowest effective dose of 






Figure 10. Deprivation induced chow intake at three different doses of simvastatin 
over a four-hour time period. Error bars indicate standard error of the mean (SEM). 




6.10.2 Experiment two: Effect of Simvastatin on overnight chow intake  
 Without food deprivation, meal times are less profound than in experiment one.  
The animals administered with simvastatin ate more chow than the control group 
up to four hours after injection, with a significant difference between the 
simvastatin and control group at three hours. After four hours, the animals 




Figure 11. Overnight food intake after 30nmol simvastatin vs control over a 12-hour 
time period. Error bars indicate standard error of the mean (SEM).   




6.10.3 Experiment three: Effect of Simvastatin on deprivation induced 
palatable food intake 
The palatable food solutions of sucrose, saccharin and sweetened milk were 
selected because sucrose was used as a high calorie food item, while saccharin 
contains the sweet taste without the calories. Sweetened milk contains less 
calories than sucrose, but includes other flavour compounds such as fat which 
adds complexity to the taste (Swiergiel, Smagin, & Dunn, 1997). 
Animals administered with simvastatin drank a similar amount of all three 
palatable foods (sucrose, saccharin and sweetened milk) two hours after injecting 
when compared to the control animals (Figure 12).   
 
  
Figure 12. Palatability-driven food intake, two hours after injection of 30nmol 




6.10.4 Experiment four: Effect of Simvastatin on deprivation induced water 
consumption 
The group of animals administered with simvastatin drank a significantly (15%) 
more water than the control group two hours after injecting (Figure 13). 
 
  
Figure 13. Water intake after deprivation, two hours after injection of 30nmol 
simvastatin vs control. Error bars indicate standard error of the mean (SEM). 




6.10.5 Experiment five: Effect of Simvastatin on c-Fos immunoreactivity 
Animals administered with simvastatin had a significant increase in c-Fos 
immunoreactivity when compared to controls in the PVN and ARC (Figure 14). 
There was an increase in activation of approximately 50% and 29% in the PVN 
and ARC respectively.  
All other areas has similar levels of immunoreactivity, with no significant 





Figure 14. c-Fos immunoreactivity in different brain regions following injection of 30nmol 
simvastatin vs control. Error bars indicate standard error of the mean (SEM). 
* indicates 5% significance.  
PVN – paraventricular nucleus, SON – supraoptic nucleus, DMH - dorsomedial hypothalamic nucleus, VMH - 
ventromedial nucleus of hypothalamus, ARC – arcuate nucleus, LHA – lateral hypothalamic area, NTS – nucleus 





The key findings of this research showed that simvastatin is able to increase FI 
when delivered centrally. This increase is related to FI for energy, with no 
influence from food palatability, and surprisingly also increased water 
consumption.   
The results showed an increase in chow intake with and without deprivation by 
administering simvastatin centrally (experiments one and two). The idea that 
simvastatin could have an impact on the periphery causing a change in FI, in the 
context of this study, was dismissed. Peripheral influences may have some impact 
with different types of administration of simvastatin, such as intraperitoneal or 
oral. However, these results were able to show that regardless of peripheral 
interaction, FI increase still occurred due to the engagement of central 
mechanisms.  
With further investigation into these central mechanisms, it is strongly suggested 
that simvastatin influences central pathways controlling food intake for energy 
and not for pleasure. Evidence for this was provided by food intake studies 
(experiment three) demonstrating in animals that were not water deprived, the 
same amount of palatable solutions were consumed between simvastatin and 
control groups. This finding was further supported by c-Fos immunoreactivity 
studies showing key areas of the brain involved in eating for energy, PVN and 
ARC, (experiment five) were 50% and 29% more active in animals that have been 
administered simvastatin. There are many possible mechanisms which may be 
responsible for the FI differences seen between simvastatin and control groups. 




This system comprises of two neuronal pathways; NPY/AgRP and POMC/CART 
neurons, within the ARC which project to the PVN and have downstream impacts 
effecting FI for energy. The increase in FI may be explained by simvastatin 
interacting with NPY/AgRP neurons, eliciting an increase in FI, or perhaps 
simvastatin inhibits POMC/CART neuron impeding their ability to cause a 
reduction in FI.  
Another possible explanation involves the ARC and PVNs influence on brown 
adipose tissue (BAT) metabolism. BAT has a crucial role in body heat production 
helping maintain thermal homeostasis, as well as having an influence on body 
weight regulation (Rothwell & Stock, 1979). In a cold environment, BAT 
produces heat that is used to keep the internal body temperature constant and 
prevent hypothermia (Rothwell & Stock, 1979). This is called cold-induced 
thermogenesis. However, during over eating BAT also produces heat, and this is 
thought to occur as a protection mechanism from obesity (Cannon & Nedergaard, 
2004). This is called diet-induced thermogenesis, where the increase in EE 
attempts to compensate for the extra calories that are consumed (Cannon & 
Nedergaard, 2004). POMC/CART neurons in the ARC increase FI, but are also 
able to increase BAT thermogenesis (Münzberg, Qualls-Creekmore, Berthoud, 
Morrison, & Yu, 2016). When α-MSH is secreted from POMC/CART neurons, 
MC4Rs are activated which causes an increase in EE by activating BAT 
thermogenesis. While there are MC4Rs in the PVN, it is critical to note that these 
receptors so not have an influence on EE. There are MC4Rs elsewhere which 
contribute to EE, but the exact sites of MC4R mediated BA thermogenesis are still 
unknown (Münzberg et al., 2016). There are also non-NPY/AgRP and non-
POMC/CART neurons within the ARC which effect FI and EE (Kong et al., 
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2012). A portion of these neurons are called RIP-cre neurons which are 
distributed amongst NPY/AgRP and POMC/CART neurons, but are distinctly 
different. Manipulation of these neurons has shown that the release of GABA 
from RIP-cre neurons has an effect on energy balance. GABA released from these 
RIP-cre neurons in the ARC is suggested to provide input to the PVN, which 
sends projections to the NTS, causing an increase in EE by stimulating BAT. 
However, the increase of EE by RIP-cre neurons cannot be explained by the 
increase BAT thermogenesis alone, suggesting these neurons may also effect 
other areas of metabolism. Because the c-Fos immunoreactivity data did not show 
an increase in c-Fos activation (between control and simvastatin groups) in the 
NTS, it is unlikely this is causing the observed increase in FI. However, RIP-cre 
neurons are found in many regions throughout the brain suggesting a different 
population of RIP-cre neurons may be causing the observed increase in FI. It is 
still unknown which RIP-cre neurons are solely responsible for the regulation of 
EE, and the key neurotransmitters and downstream systems are also unknown 
(Kong et al., 2012). Therefore, simvastatin may be causing an increase in FI by 
increasing the activation of POMC/CART neurons to produce more α-MSH. This 
may activate MC4Rs outside of the PVN which increases BAT thermogenesis 
induced EE. Alternatively, perhaps simvastatin increases activation of RIP-cre 
neurons in the ARC which releases GABA to affect some undetermined brain 
region, causing an increase in BAT thermogenesis induced EE. Without additional 
research, it is difficult to narrow down which central mechanism is causing the 
increase in FI simvastatin causes. However, these two suggested mechanisms are 
only possible explanations. There are many other systems within the brain which 
may be having an influence on FI and EE.  
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Surprisingly, when animals were deprived of water the simvastatin group drank 
15% more than controls (experiment four). Water balance is controlled by three 
systems; arterial baroreflex system, renin-angiotensin pathway and 
osmoreceptors.  
Baroreceptors are sensitive to changes in pressure and are found throughout the 
cardiovascular system. They are present in the arteries which can detect both high 
and low blood pressure (Stauss, 2002; Terry N. Thrasher, 1994). When blood 
pressure is normal, baroreceptors send excitatory signals to the brain which 
inhibits the release of vasopressin, and during low blood pressure the inhibitory 
signal causes an increase in vasopressin release (Stauss, 2002; Terry N. Thrasher, 
1994). Baroreceptors are also located in the carotid sinus and aortic arch. These 
baroreceptors are suggested to have a key role in the regulation of blood volume 
(Gabrielsen et al., 2000). When blood pressure drops, carotid and aortic 
baroreceptors signal to the brain to release vasopressin and in order to increase 
water reabsorption. Carotid baroreceptors signal communicate with the brain 
through the glossopharyngeal nerve, while aortic baroreceptors communicate 
through the vagus nerve (Wehrwein & Joyner, 2013). Both of these nerves end in 
the NTS where signals can be carried through to the hypothalamus (Wehrwein & 
Joyner, 2013).  
The renin-angiotensin-aldosterone system (RAAS) is another way osmolarity and 
blood volume is regulated. A decrease in blood salt levels or blood pressure can 
be detected by receptors on juxtaglomerular cells in the kidney (Castrop et al., 
2010). When these receptors are activated, they cause the release of a secondary 
messenger, cAMP, to stimulate the production of pre-pro-renin which is cleaved 
to form pro-renin. Pro-renin can be secreted into the bloodstream through the 
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constitutive pathway and is converted into active renin in the blood stream. 
However, when salt concentrations are significantly low, both pro-renin and renin 
will be secreted from the cell through the regulated pathway into the blood stream 
(Castrop et al., 2010). Once active, renin within the blood stream can cleave 
hepatically produced angiotensinogen to form angiotensin 1 (Lu, Cassis, Kooi, & 
Daugherty, 2016). This is the rate limiting step of the renin-angiotensin system 
(Lu et al., 2016). β1-adrenergic receptors within cardiac tissue are also able to 
cause the release of renin from juxtaglomerular cells through the activation of the 
fight or flight response. Angiotensin-converting enzyme in the blood is then able 
to cleave angiotensin I into angiotensin II. Angiotensin II is involved in several 
functions such as vasoconstriction, aldosterone release and vasopressin release, in 
order to increase blood pressure and normalise osmolarity. This is triggered by the 
binding of angiotensin II to AT1 receptors (Lu et al., 2016). Aldosterone secretion 
from adrenal glands is able to increase sodium retention from the distal tubule and 
collecting duct of the nephron through active transport using a Na+/K+ pump 
(Horton, 1973). This also passively transports water from the distal tubule and 
collecting duct (Horton, 1973). The binding of aldosterone creates a negative 
feedback loop inhibiting the secretion of renin (Lu et al., 2016). The release of 
vasopressin from the pituitary also initiates thirst (Lu et al., 2016). Vasopressin 
release causes vasoconstriction through binding to the V1 receptor (Holmes, 
Landry, & Granton, 2003). The binding of vasopressin to V2 receptors in the 
kidney increases the expression of aquaporin two on the apical membrane of the 
collecting duct. This increases the flow of water into the blood stream through 
permanent aquaporins three and four (Holmes et al., 2003). However, when blood 
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volume is normal, baroreceptors are able to inhibit renin and vasopressin (T. N. 
Thrasher, 1994). 
Osmoreceptors in the hypothalamus react to changes in osmolarity in CSF which 
mirrors the osmolarity of the blood (Salata, Jarrett, Verbalis, & Robinson, 1988). 
When CSF becomes less dilute it sends signals through the magnocellular neurons 
from either the SOP or PVN, which then causes the release of vasopressin from 
the posterior pituitary. Vasopressin release also increases ACTH release from 
anterior pituitary to stimulate the HPA axis. The downstream release of cortisol, 
like aldosterone, also causes the conservation of sodium (Salata et al., 1988).   
These three mechanisms maintain water balance by restoring osmolarity, however 
the mechanisms behind the sensation of thirst are largely unknown (Verbalis, 
2007). Neural circuits from the magnocellular neurons project into the forebrain. 
Therefore, secretion of vasopressin may also trigger a parallel pathway to initiate 
thirst (Verbalis, 2007).   
Because baroreceptors and the renin-angiotensin system are controlled in the 
periphery, it is unlikely simvastatin is influencing these mechanisms because it 
was delivered centrally. The interaction of simvastatin with osmoreceptors 
causing their activation or dysfunction, which subsequently releases vasopressin is 
a possible reason for this increase in water intake. This is further supported by the 
c-Fos results which showed increased activation in the PVN, which could 
potentially be caused by the release of vasopressin. Simvastatin could also be 
inducing the increase in water intake due to an increase FI altering the osmolarity 
of the blood, causing the release of vasopressin to correct this.  
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The finding that simvastatin is able to effect brain regions related to water balance 
supports the hypothesis that simvastatin has an effect on eating for energy due to a 
change in EE. Both the ARC and PVN are involved in food and water intake 
regulation, which supports the notion that simvastatin is effecting central 
mechanisms within the ARC and PVN, causing an increase in food and water 
intake, potentially due to a change in EE.  
In conclusion, central infusion of simvastatin causes an increase in food and water 
consumption due to a change in FI or EE regulation. The influence of simvastatin 
on food and water consumption is likely occurring within the ARC and/or PVN of 
the hypothalamus. Although the exact mechanisms of how this occurs are 
unknown, it could be an interaction with either FI pathways in the ARC, such as 
the melanocortin pathway or RIP-cre neuronal pathway. A change in EE is 
supported by the unexpected increase in water intake, which central simvastatin 
elicited. Although the exact mechanisms of how this occurs is also unknown, it 




6.12 Possible clinical implications and perspectives 
Simvastatin targets central pathways involved in FI and/or EE to create an 
increase in food and water consumption. This information gives some potential 
clinical implications that should be addressed. The fact that simvastatin is having 
a central effect causing these changes suggests that simvastatin crossing the BBB 
is inducing adverse effects counterproductive for the reduction of LDL-C. With 
this information, it may be essential to modify lipophilic statins so they cannot 
cross the BBB. This could either be done by modifying the molecular structure of 
the statin to make it more hydrophilic, or by administering a separate drug which 
can prevent simvastatin from crossing over the BBB.  
Perhaps the use of stains needs to be reviewed. It has been almost 50 years since 
statins were first introduced as a drug to prevent CVD, and although their 
efficiency at doing this is satisfactory, with more research and information 
available on the progression of atherosclerosis and CVD susceptibility it may be 
time to revise our understanding of a variety of effects induced by these drugs. 
More information is now available on the functional mechanisms of how statins 
decrease LDL-C levels, which can be used for their improvement. However, new 
components involved in cholesterol production such as CETP, LDL receptor and 
ACAT activity are being uncovered that could be explored as potential targets for 
therapy as well as HMGR.  
Although statins do have some adverse effects, they do decrease LDL-C levels to 
a point where patients’ CVD risk is drastically reduced, increasing their quality of 
life as well as prolonging it. Statins are shown to be safe for long-term use, and 
there are several drugs of this class to choose from to fit an individual patient’s 
responsiveness to the treatment. It is imperative to understand that although statins 
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come with some risk of adverse effects, the benefits of statin use greatly outweigh 
their side effects. They are an essential drug for our current obesogenic 
environment.  
Certainly, double staining immunohistochemistry for the different hypothalamic 
neurons of interest (NYP/AgRP, POMC/CART, RIP-cre) to see whether there is 
increased activation in these neurons should be done in the future. This would 
shed more light on the central mechanisms causing the increase in food and water 
consumption. Also, including an analysis of gene expression in the hypothalamus 
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